Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company

NEXT STORY
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
PREV STORY
Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma

Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for ...

author_avatar
NASDAQ Market News

Johnson & Johnson Veteran Chuck Austin To Scale Up BioSig Operations

author_avatar
NASDAQ Market News

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

author_avatar
NASDAQ Market News